GlaxoSmithKline plc (LSE/NYSE: GSK) today presented data from the pivotal Phase III STABILITY study of darapladib at the American College of Cardiology 63rd Annual Scientific Session in Washington, DC. The data have also been published in the New England Journal of Medicine. Darapladib is not approved for use anywhere in the world.
↧